2LOK A S, MCMAHON B J. Chronic hepatitis B [ J ]. Hepatology,2001, 34(6) :1225.
3UNGO J R, JONES D, ASHKIN D,et al. Antituberculosis druginduced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus[ J ]. Am J Respir Crit Care Med, 1998,157 ( 6 pt 1) :1871.
4YEE D, VALIQUETTE C, PELLETIER M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis [ J ]. Am J Respir Crit Care Med, 2003,167(11) :1472.
1MOULDING T. A randomized controlled trail of high-dose isoniazid adjuvant therapy for muhidrug-resistant tuberculosis[J]. Int J Tuberc Lung Dis,2008,12 (10) : 1102.
2KATIYAR S K, BIHARE S, PRAKASH S, et al. A randomized controlled trail of high-dose isoniazid adjuvant theraphy for muhidrug-resistant tuberculosis [ J ]. Int J Tuberc Lung Dis, 2008,12 ( 1 ) : 139 - 145.
3NAM H S, KOH W J, KWON O J, et al. Daily half-dose linezolid for the tretment of intractable multidrug-resisttant tuberculosis [ J ]. Int J Antimicrob Agents, 2009,33 ( 1 ) : 92 - 93.
4CAMINERO J A , World Health Organization, American Thoracic Society, et al. Treatment of mutidrug-resistant tuberculosis:evident and controversies [ J ]. Int J Tuberc Lung Dis ,2006,10(6) :829 - 837.
5TUPASI T E, GUPTA R, QUELAPIO M I, et al. Feasiblity and cost-effectiveness of treating multidrug-resistant tuberculosis, a cohort study in the Philippines [ J ]. Plos Meal,2006,3 (3) : 352.
